Congress of the French Society of Bone Marrow TransplantationHematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 192-212, issn 1269-3286Conference Proceedings

G-CSF : a very efficient therapy in chronic autoimmune neutropenia. A brief review of the literatureBAUDUER, F.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 189-191, issn 1269-3286Conference Paper

Leucémie myéloïde chronique : application à la clinique de la thérapie cellulaire et génique = Chronic myelogenous leukaemia : clinical application of gene and cellular therapyREIFFERS, J.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 247-250, issn 1269-3286Conference Paper

Interferon-α : mechanisms of action in chronic myelogenous leukemia in chronic phaseGUILHOT, F; LACOTTE-THIERRY, L.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 237-239, issn 1269-3286Conference Paper

Chimiothérapie, interféron et facteurs de croissance dans la séléction des cellules Philadelphie négatives = Chemotherapy, interferon, and growth factors in chronic myelogenous leukaemiaMICHALLET, M; THIEBAUT, A.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 241-246, issn 1269-3286Conference Paper

Anti-phospholipid syndrome : from patient's bedside to experimental animal models and back to the patient's bedsideZIPOREN, L; SHOENFELD, Y.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 175-182, issn 1269-3286Conference Paper

Minimal residual disease in chronic myeloid leukaemiaCROSS, N. C. P.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 224-228, issn 1269-3286Conference Paper

CML and apoptosis : the Ceramide pathwayMAGUER-SATTA, V.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 233-236, issn 1269-3286Conference Paper

Gene therapy for chronic myelogenous leukemiaVERFAILLIE, C. M; ZHAO, R. C; MCIVOR, R. S et al.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, issn 1269-3286, p. 240Conference Paper

Immunotherapy for chronic myeloid leukaemiaAPPERLEY, J. F; DAZZI, F; CRADDOCK, C et al.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 229-232, issn 1269-3286Conference Paper

Perspectives d'immunothérapie cellulaire adoptive ou vaccinale de la leucémie myéloïde chronique = Cellular adoptive or vaccinal immunotherapy in chronic myloid leukaemiaBUZYN, A; OSTANKOVITCH, M; VARET, B et al.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 222-223, issn 1269-3286Conference Paper

Molecular pathophysiology of chronic myelogenous leukemiaTURHAN, A. G; SOLARY, E; VAINCHENKER, W et al.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 217-221, issn 1269-3286Conference Paper

Allogeneic bone marrow transplantation for agnogenic myeloid metaplasiaGUARDIOLA, P; ESPEROU, H; GLUCKMAN, E et al.British journal of haematology. 1997, Vol 98, Num 4, pp 1004-1009, issn 0007-1048Article

Quantification of apoptosis by the Abbott CD4000 hematology analyzerMENTZ, F; BAUDET, S; MALOUM, K et al.Hematology and cell therapy (Print). 1998, Vol 40, Num 5, pp 183-188, issn 1269-3286Conference Paper

Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemiaGUARDIOLA, Philippe; KUENTZ, Mathieu; TANGUY, Marie-Laure et al.British journal of haematology. 2000, Vol 111, Num 1, pp 292-302, issn 0007-1048Article